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ADAMTS-18 in the host tissues exerts little
effect on breast tumor progress in a
murine 4T1 breast cancer model
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Abstract
Background: In this study, we aimed to identify a novel extracellular proteinase ADAMTS-18 that could be a potential
tumor suppressor gene.
Results: We successfully constructed Adamts-18 knockout mice with BALB / c background. RT-PCR analysis showed
syngeneic mammary tumor cell line 4 T1 per se has weakly endogenous ADAMTS-18 expression. Orthotopic
inoculation of 4 T1 cells within the mammary fat pad of host mice, we found no significant difference in tumor growth
and metastasis between Adamts-18 knockout mice and widetype control.
Conclusions: We did not confirm that ADAMTS-18 in the host tissues is relevant for breast tumor progress in a murine
4 T1 breast cancer model.
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Background
Matrix metalloproteinases are traditionally linked to
tumor dissemination through their ability to degrade most
extracellular matrix (ECM) components, thus facilitating
tumor cell invasion and metastasis [1]. However, recent
studies suggest that some metalloproteinases contribute
to inhibit tumorigenesis [2]. ADAMTS-18 (a disintegrin
and metalloproteinase with thrombospondin motif 18), as
yet no known function or substrate, is a member of
ADAMTS family of secreted proteinases. It has been
shown that ADAMTS-18 gene was inactivation in many
carcinomas especially breast tumors and, therefore, is
regarded as a novel functional tumor suppressor [3]. We
previously reported that the C-terminal ADAMTS-18
fragment induces oxidative platelet fragmentation, dis-
solves platelet aggregates, and protects against carotid
artery occlusion and cerebral stroke [4]. To further study
the role of ADAMTS-18 in vivo, we generated Adamts-18
knockout mice (unpublished data). The aim of this study
was to investigate the effect of ADAMTS-18 on tumori-
genesis in a murine 4 T1 breast cancer model.
Methods
Animal studies
In our laboratory Adamts-18 heterozygote mice (Adamts-
18+/-) with C57BL6/129SV were developed (unpublished
data). They backcrossed to wild-type BALB/c mice for 7
generations to obtain BALB/c background Adamts-18+/-
mice. Adamts-18+/- mice with BALB/c background are
intercrossed to generate Adamts-18 knockout mice
(Adamts-18-/-) and wildtype control (Adamts-18+/+) for
further experiment. Syngeneic mammary tumor cell
line 4 T1 cells were orthotopically implanted within the
mammary fat pad of females aged 8–10 weeks. Cells im-
plantation in the mammary fat pad was achieved using a
(1/2)- inch 26 gauge needle and gentle pressure during de-
livery of 100 μl cells. Mice were watched daily to monitor
the growth of the tumor and once a substantial size of
tumor mass was found, the mice were sacrificed and the
tumor mass were collected and weighted. The surface
metastatic nodules on the lungs and other organs were
counted, and then histologic analyses were performed. All
procedures in animal experiments were approved by the
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Institutional Animal Care and Use Committee of East
China Normal University (ECNU). All the mice used in this
study are female and maintained in a specific pathogen-free
facility at ECNU.
Western blotting
Proteins from the brain, kidney, liver or xenograft tumors
of both mice were separated on a 12 % SDS–PAGE under
reducing conditions and then transferred onto a polyviny-
lidene difluoride (PVDF) membrane. The membrane was
blocked in blocking buffer (PBS, 0.5 % Tween-20, and 5 %
non-fat dry milk powder) and then incubated with rabbit
anti-ADAMTS18 IgG (sc-68416, Santa Cruz Biotechnol-
ogy, Inc.) for 1 h at RT. After washing, the membrane was
incubated with horseradish peroxidase (HRP)-conjugated
secondary antibody for 1 h at RT. The immunoreactive
bands were visualized with enhanced chemiluminescence
(ECL) western blot kit.
Semi-quantitative RT-PCR analysis
The endogenous expression level of ADAMTS-18 gene in
murine 4 T1 tumor cells was detected by semi-quantitative
RT-PCR. Total RNA was isolated from cultured cells using
the TRIzol reagent according to the manufacturer’s proto-
col (Invitrogen, Carlsbad, CA, USA). Semi-quantitative
RT-PCR was performed with cDNA reverse-transcribed
from 1 μg of total RNA using AMV reverse transcriptase
(Takara, Otsu, Japan). The cycle threshold values were
normalized to the expression of the housekeeping gene
β-actin. Band density was scanned and calculated. The
primers are list as following: β-actin forward: 5′-ACGG
CCAGGTCATCACTATTG-3′, β-actin reverse: 5′-CCT
GCTTGCTGATCCACATCT; ADAMTS-18 forward
(mouse specific): 5′-TGGAAAGTCACAAAATGGTCT
CA-3′; ADAMTS-18 reverse (mouse specific): 5′- AAC
CACAATGTTTATGTCGCTTC-3′.
Histological analysis
Tumor tissues were fixed in 10 % formaldehyde in
phosphate-buffered saline (PBS), pH 7.4, dehydrated
and embedded in paraffin and sectioned with a micro-
tome. Tumor malignant degree and mitotic counts in
sections were evaluated by hematoxylin and eosin (H.E)
staining. Intratumoral vascular density was assessed by
Fig. 1 Generation and characterization of Adamts-18 knockout mice with BALB/c background. a The mating strategy for producing BALB/c inbred
Adamts-18 knockout mice; (b) PCR genotyping of wildtype (WT), heterozygote (HT), and knockout (KO) mice; (c) Western blot analysis of Adamts-18 in
kidney, liver, and brain from different mice, β-actin was used as a loading control. WT, wild-type mouse; KO, knockout mouse. d Incidence rate of breast
cancer in different generation of mice with BALB/C background; (e) Bearing-tumor mice number in the seventh generation of BALB/c inbred mice after
orthotopically implanted within the mammary fat pad of mice with different dose of 4 T1 cells. f Representative photograph of breast tumor. Arrow
refers to breast tumor; (g) Representative HE staining, bar = 50 μm
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staining with goat anti-mouse CD31 antibody (Santa Cruz
Biotechnology Inc., CA). Microvessel density (MVD) was
determined by light microscopy in areas of invasive tumor
containing the highest numbers of capillaries and microves-
sels per area. MVD was expressed as the number of micro-
vessel per high-power field.
Statistical analysis
P values were determined through the two-tailed Student’s
t test. Data are presented as mean ± SD. Differences were
considered statistically significant when P < 0.05.
Results and discussion
The potential role of ADAMTS-18 in tumor genesis is first
suggested by the genetic analysis [5]. It has been shown
that the loss of 16q23 region is strongly associated with a
variety of cancers. Since ADAMTS-18 is one of these
genes located around 16q23 region, it has been studied as
a candidate oncogene [3, 5–10]. Because ADAMTS-18
is often inactivated in breast tumors, we therefore de-
velop Adamts-18 knockout mouse with BALB/c back-
ground, and inoculate syngeneic mammary tumor cell
line 4 T1 cells to evaluate the role of ADAMTS-18 in
breast cancer.
Fig. 2 Syngeneic mammary tumor cell line 4 T1 subcutaneously transplanted growth. a The endogenous ADAMTS-18 expression in cultured 4 T1
cells (upper panel) or in xenograft 4 T1 tumors (lower panel). MEF, mouse embryonic fibroblast; bp, base pair; MW, molecular weight; **indicates
P < 0.01. b Mice were challenged with 106 4 T1 cells, and tumor volumes were monitored for six weeks. c Survival rate of mice; (d) Final tumor
weight in different genotype of mice. Adamts-18+/+, wildtype mice; Adamts-18-/-, knockout mice. e CD31 (40 ×magnification) positive microvessels
in each group (n = 5/group). Data are expressed as mean ± SD
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Fig. 3 Tumor metastasis in different genotype of mice. a Systemic tumor metastasis; (b) Representative photograph of lung metastasis;
(c) Representative HE staining of lung metastasis; (d) Bar graph showing statistic analysis of lung tumor nodes
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First, Adamts-18 heterozygote mice (Adamts-18+/-) with
C57BL6/129SV background were backcrossed to wild-type
BALB/C mice for 7 generations to obtain Adamts-18+/-
mice with BALB/ c background. They are intercrossed to
get Adamts-18 knockout mice (Adamts-18-/-) and wildtype
control (Adamts-18+/+) for further experiment (Fig. 1a-b).
Immunoblot analysis for ADAMTS-18 expression in dif-
ferent tissues from both mice further confirmed the
knockout effectiveness (Fig. 1c). The results of orthotopic
inoculation of syngeneic mammary tumor cell line 4 T1
cells (106/mouse) within the mammary fat pad showed
that the percentage of tumor incidence reached 100 %
after six and seven generations (Fig. 1d). In the seventh
generation of mice, 10 of 10 mice bear tumor when the in-
oculation doses of 4 T1 cells were 106 per mice (Fig. 1e).
Representative photograph of breast tumor (Fig. 1f) and
hematoxylin-eosin (HE) staining are shown (Fig. 1g).
The effect of tumor growth in some extent depends on
tumor cell line per se. It has been shown that the expres-
sion of ADAMTS-18 was dramatically reduced or totally
silenced in multiple human cancer cell lines, including cell
lines of human breast cancer (BT549, MB231, MCF-7,
and YCC-B1) due to methylation of promoter CpG Ilands
(CGI) [5]. To test the expression level of ADAMTS-18 in
murine 4T1 cells, RT-PCR was performed and the result
showed 4T1 per se has weakly endogenous ADAMTS-18
expression (Fig. 2a, upper panel). In this regard, 4T1-
knockout ADAMTS-18 cell line is needed in future
studies. We then injected 4T1 cells to both Adamts-18
knockout mice (Adamts-18-/-) and wildtype control
(Adamts-18+/+) mice. The result of Western blotting
showed that the Adamts-18 expression is ~3.6 fold higher
in xenograft tumors of WT mice than in KO mice (n = 3,
**P < 0.01) (Fig. 2a, lower panel). However, we found no sig-
nificant differences in tumor growth, survival rate of mice,
tumor weight between Adamts-18-/- and Adamts-18+/+
mice (Fig. 2b-d). There was no significant difference in
tumor malignant degree and mitotic counts between
Adamts-18+/+ and Adamts-18-/- mice [mitotic counts, WT
vs. KO, 10.75 ± 2.1 vs. 11 ± 1.4 per high power field (HFP),
n = 8/group, P = 0.826). Moreover, microvessel density
(MVD) had no significant difference between Adamts-18+/+
and Adamts-18-/- mice (MVD, WT vs. KO, 64 ± 6 vs. 67 ±
11 per high power field (HFP), n = 5/group, P = 0.947)
(Fig. 2e). There is no significant difference in systemic
metastasis (Fig. 3a), especially lung metastasis (Fig. 3b-d)
between Adamts-18+/+ and Adamts-18-/- mice. These re-
sults indicated that ADAMTS-18 in host tissues (e.g.
stroma components, endothelium, tumor-associated fibro-
blasts, and immune cells etc) likely exerts little effect on
breast tumor progress. However, further studies are needed
to assess the effect of ADAMTS-18 on other tumor types
(e.g. melanoma, spontaneous cancers, etc) or its synergy
effect with other tumor-related genes.
Many ADAMTSs have proved to be anti-angiogenic
through their metalloproteinase-dependent and –inde-
pendent activities, which contribute to inhibit cancer
development and progression. ADAMTS-1 displays both
types of mechanism [11]. It induces the generation of
anti-angiogenic fragments by cleaving matrix-bound
thrombospondins-1 and -2 [12], and also sequesters an-
giogenic factors such as the basic fibroblast growth factor
(bFGF) and vascular endothelial growth 1(VEGF165)
[13, 14]. ADAMTS-9 also demonstrates metalloproteinase-
dependent and –independent activities, but the mechanism
remains unclear [15]. Other ADAMTSs, including
ADAMTS-2, -4, -5, and -12, displays metalloproteinase-
independent inhibition of neovascularization, which is
closely related to their thrombospondin type 1 se-
quence repeat (TSR) domain [16–19]. The peptides
(termed Adamtsostatins) corresponding to the TSRs of
some family members have anti-angiogenic properties,
indicating that this may be a general activity of ADAMTSs.
In this study, we didn’t find difference in microvessel dens-
ities of tumors between Adamts-18+/+ and Adamts-18-/-
mice. Nevertheless, more sophisticated assays for angio-
genesis such as wound healing, tube formation, and
ischemia assays are needed in future studies.
Conclusions
The current data suggest that the murine 4 T1 breast
tumor cell per se has weakly endogenous ADAMTS-18
expression, and ADAMTS-18 in the host mouse exerts
little effect on breast tumor progression in murine 4 T1
breast cancer model.
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